Pfizer's Sales Warning & Pipeline Concerns

about 1 month ago

Carmen Reiniki

"This is ticker PFE. So, it's down about 4 and a.5% right now. Um, the drug maker forecasts little to no sales growth next year. Um, so it's sort of a warning sign for the drug maker. Um, it's looking to rebuild its pipeline of hit drugs. I think the stock is still down, you know, 50% since COVID, you know, in trying to sort of rebuild that. Um, and it also comes sort of after a series of pricey acquisitions that the company has made. So basically they said revenue in 2026 will be between 5.5 billion to 26 1.5 billion and that really fell below the midpoint of what analysts were expecting in that time period."

The discussion highlights Pfizer's forecast of little to no sales growth next year along with significant pipeline rebuilding challenges and expensive acquisitions, indicating caution due to the stock's steep decline since COVID.

Related Stocks